Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

NCT03471663 is registered in ClinicalTrials.gov with InventisBio Co., Ltd as lead sponsor.

NCT NCT03471663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03471663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
Lead sponsor
InventisBio Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
March 18, 2018
Completion date
October 18, 2023
Enrollment
200 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer